Education
About Us
Working with TipRanks
Follow Us
NanoViricides (NNVC)
XASE:NNVC
NNVC Stock Chart & Stats
$1.13
-$0.10(-6.54%)
At close: 4:00 PM EST
$1.13
-$0.10(-6.54%)
Day’s Range― - ―
52-Week Range$0.85 - $2.23
Previous CloseN/A
Volume409.80K
Average Volume (3M)143.34K
Market Cap
$22.24M
Enterprise Value-$5.15T
Total Cash (Recent Filing)$5.15T
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Nov 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding21,595,000
10 Day Avg. Volume199,739
30 Day Avg. Volume143,335
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap-231.56K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.88M
Enterprise Value/Ebitda667.80K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA near-zero debt profile materially reduces solvency and interest-rate risk, giving management flexibility to prioritize R&D and clinical programs without high fixed financing costs. This strengthens the firm's financial optionality when raising equity or negotiating partnerships over the medium term.
Proprietary PlatformOwning a distinct nanoviricide platform provides durable competitive differentiation in broad-spectrum antivirals. If clinical validation progresses, the platform supports multiple indications and licensing/co-development pathways, creating structural upside via partnerships and non-dilutive milestone revenue opportunities.
Lean Operating FootprintA very small headcount indicates a lean cost base and lower fixed overhead, which can stretch available cash and reduce near-term burn relative to larger peers. This operational compactness supports resource-efficient execution of targeted R&D programs while management pursues partnerships or external funding.
Bears Say
No RevenueThe absence of any commercial revenue leaves the company fully dependent on capital markets and third-party funding rather than operational cash generation. Without validated product sales, long-term profitability and organic cash generation remain highly uncertain and contingent on successful clinical outcomes.
Persistent Cash BurnConsistent operating and free cash outflows indicate real, sustained cash burn rather than paper losses. This creates recurring financing requirements, increases dilution risk over time, and constrains strategic flexibility to advance multiple programs simultaneously without external capital or partners.
Eroding Equity Base / Dilution RiskA materially declining equity base reflects cumulative losses and prior financing/dilution, reducing the firm's balance-sheet cushion. This trend signals heightened probability of future equity raises, which can dilute existing holders and may limit bargaining power in partnership or licensing negotiations.
NanoViricides News
NNVC FAQ
What was NanoViricides’s price range in the past 12 months?
NanoViricides lowest stock price was $0.85 and its highest was $2.23 in the past 12 months.
What is NanoViricides’s market cap?
NanoViricides’s market cap is $22.24M.
When is NanoViricides’s upcoming earnings report date?
NanoViricides’s upcoming earnings report date is Nov 23, 2026 which is in 245 days.
How were NanoViricides’s earnings last quarter?
NanoViricides released its earnings results on Nov 24, 2025. The company reported -$0.135 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.045.
Is NanoViricides overvalued?
According to Wall Street analysts NanoViricides’s price is currently Overvalued.
Does NanoViricides pay dividends?
NanoViricides does not currently pay dividends.
What is NanoViricides’s EPS estimate?
NanoViricides’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoViricides have?
NanoViricides has 21,595,000 shares outstanding.
What happened to NanoViricides’s price movement after its last earnings report?
NanoViricides reported an EPS of -$0.135 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -2.362%.
Which hedge fund is a major shareholder of NanoViricides?
Currently, no hedge funds are holding shares in NNVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NanoViricides
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Technical Analysis
Ownership Overview
―
Insiders
3.13% Mutual Funds
7.23% Other Institutional Investors
87.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---